company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12549459.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12549459.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2951489.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2951489.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9597970.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23925585.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7867398.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31792983.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22195013.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1507059.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,367776.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,5365.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1133918.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23328931.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23328931.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23328931.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23328931.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.62
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.62
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37708252.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q2,2009-04-01,2009-06-30,2010-08-09 17:17:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.62
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15214321.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15214321.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2602064.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2602064.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12612257.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23415132.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8197789.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31612921.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19000664.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,704229.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,314000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-38914.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-429143.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19429807.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19429807.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19429807.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19429807.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37749920.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.51
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37749920.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:32:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.51
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17747000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17747000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3076000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3076000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14671000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26714000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8062000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34776000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20105000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1214000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,204000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1010000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21115000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21115000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21115000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21115000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38021000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.56
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38021000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.56
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37700000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q1,2010-01-01,2010-03-31,2011-05-09 07:29:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.56
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,42835000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,42835000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7832000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7832000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,35003000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34112000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6596000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40708000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5705000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1194000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,135000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1059000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6764000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6764000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6764000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6764000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38306000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38306000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:12:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,63622000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,63622000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11666000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11666000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,51956000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,30558000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7970000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,165000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38693000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,13263000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,944000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,111000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,8000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-825000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,12438000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,12438000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,12438000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,12438000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38450000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.32
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,39988000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.31
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38900000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 17:18:05+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.32
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,66801000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,66801000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12944000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12944000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,53857000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,41273000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7972000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,495000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49740000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4117000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,570000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,125000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-445000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3672000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3672000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3672000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3672000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38355000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.11
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38355000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.12
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2010.0,Q4,2010-10-01,2010-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.11
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,61286000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,61286000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12050000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12050000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,49236000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,37928000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10708000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,48795000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,441000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1136000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,140000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-996000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-555000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,117000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-672000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-672000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-672000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38781000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38781000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 15:39:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,65276000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,65276000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12048000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12048000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,53228000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40141000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12008000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,52308000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,920000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1276000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,133000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1143000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-223000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,62000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-285000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-285000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-285000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38937000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38937000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28500000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 17:12:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,93031000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,93031000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,26651000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,26651000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,66380000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34718000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9088000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,1908000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45714000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,20666000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,947000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,134000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-813000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,19853000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,986000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18867000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18867000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18867000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.48
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40174000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.47
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39300000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:55:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.48
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,72644000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,72644000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13434000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13434000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,59210000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,35721000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10304000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,158000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,46183000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,13027000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,211000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,145000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-18000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-84000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,12943000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,248000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,12695000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,12695000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,12695000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.33
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40064000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.33
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,71248000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,71248000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12464000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12464000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,58784000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,38745000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11025000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49929000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8855000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,766000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,129000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-637000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,8218000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,372000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,7846000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7846000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7846000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39340000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.2
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40407000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 11:03:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.2
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75656000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75656000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13576000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13576000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,62080000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,44230000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12634000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,158000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,57022000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5058000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,356000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,123000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-233000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4825000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,280000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4545000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4545000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4545000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39433000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.12
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40099000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.11
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37900000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 17:11:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.12
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,77437000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,77437000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14761000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14761000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,62676000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40121000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12031000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,52311000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10365000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,373000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,135000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-238000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,10127000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,533000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9594000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9594000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9594000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39463000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.24
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.24
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:23:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.24
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,81473000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,81473000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16206000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16206000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,65267000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,45594000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18191000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,158000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,63943000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1324000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,385000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,165000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-6000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-226000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1098000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-131875000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,132973000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,132973000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,132973000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39459000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.37
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,40332000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.3
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39400000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.37
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,71865000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,71865000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13484000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13484000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,58381000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48198000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12520000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,60877000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2496000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,591000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,173000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-418000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2914000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1775000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1139000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1139000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1139000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39832000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,39832000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:56:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,87053000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,87053000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16935000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16935000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,70118000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48003000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13216000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,61378000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8740000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,749000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,166000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-583000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,8157000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4247000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3910000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3910000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3910000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39960000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.1
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41583000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.09
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:42:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.1
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,84919000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,84919000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17213000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17213000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,67706000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,42336000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13839000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,56334000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11372000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,544000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,162000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-382000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,10990000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3513000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,7477000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7477000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7477000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,40315000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.19
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41996000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39400000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 15:47:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.19
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,92593000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,92593000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18377000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18377000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,74216000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,47008000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14302000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,157000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,61467000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,12749000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,286000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,167000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-119000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,12630000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6437000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6193000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6193000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6193000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,40208000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.15
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41682000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.15
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.15
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,80518000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,80518000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15529000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15529000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,64989000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,46892000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14522000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,61573000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3416000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,92000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,172000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,80000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3496000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2793000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,703000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,703000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,703000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,40934000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42235000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 17:18:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,97129000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,97129000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18899000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18899000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,78230000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,50644000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16448000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,67251000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10979000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,426000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,165000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-261000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,10718000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6033000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4685000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4685000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4685000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41032000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.11
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42432000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.11
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:49:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.11
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,105961000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,105961000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20575000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20575000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,85386000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,47820000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16578000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,64557000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,20829000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4597000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,257000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4340000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,16489000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4536000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,11953000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,11953000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,11953000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41094000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.29
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42365000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.28
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:48:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.29
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,117872000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,117872000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,24978000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,24978000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,92894000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,56457000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25922000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,157000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,6991000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,2200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,91727000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1167000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4173000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,80000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,232000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3861000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2694000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3025000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,331000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,331000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,331000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41150000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42544000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,99851000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,99851000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18446000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18446000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,81405000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48769000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30636000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,3100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,82664000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1259000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4051000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,66000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,121000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3864000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5123000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2038000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3085000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3085000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3085000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42031000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.07
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42031000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,44100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 17:08:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.07
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,113707000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,113707000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22708000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22708000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,90999000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,52819000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,31229000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,85307000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5692000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4010000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,94000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,351000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3565000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2127000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1130000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,997000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,997000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,997000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42085000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43282000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49900000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 17:25:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.02
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,148199000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,148199000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,24741000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,24741000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,123458000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,51056000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,43356000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,3200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,97771000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,25687000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4037000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,120000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-59000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3976000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,21711000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,17770000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3941000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3941000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3941000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42174000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.09
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43432000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.09
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43800000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:24:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.09
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,130903000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,130903000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,26402000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,26402000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,104501000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,52986000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,43988000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,157000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,3500000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,100631000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3870000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3374000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,160000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3216000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,654000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-8551000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9205000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9205000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9205000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42230000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43621000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.21
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42500000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,115904000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,115904000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,23186000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,23186000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,92718000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,58980000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,44570000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,6200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,109909000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17191000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3723000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,215000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,10442000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6934000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10257000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-9737000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-520000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-520000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-520000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44815000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44815000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:15:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.01
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,127458000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,127458000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,26435000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,26435000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,101023000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,62604000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,50293000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,2000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,115056000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14033000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4033000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,48000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1911000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5896000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19929000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-972000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18957000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18957000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-678000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18279000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45338000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.4
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45338000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.4
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45700000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:27:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.4
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,135613000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,135613000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,27644000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,27644000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,107969000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,54805000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,54777000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,3700000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,113441000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5472000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4404000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,46000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-179000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4537000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10009000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3023000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13032000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13032000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-307000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12725000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45378000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45378000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.28
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45378000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:26:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,140626000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,140626000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,30210000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,30210000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,110416000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,59048000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,53797000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,157000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-3300000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,109702000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,714000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4367000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,30000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1550000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2787000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2073000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1021000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3094000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3094000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3094000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45259000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.07
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45259000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.07
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,119386000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,119386000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,25183000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,25183000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,94203000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,52024000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,46493000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,10800000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,109476000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15273000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4143000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,38000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-444000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4549000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19822000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-918000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18904000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18904000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18904000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45808000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 07:22:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,139438000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,139438000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,29665000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,29665000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,109773000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,49334000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,51184000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,6400000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,107077000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2696000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5460000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,35000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5421000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2725000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5471000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8196000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8196000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8196000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45943000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45943000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45500000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 06:52:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,141065000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,141065000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,29992000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,29992000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,111073000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40741000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33286000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,39446000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-400000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,113232000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2159000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4180000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,30000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-18000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4168000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6327000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,18868000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25195000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25195000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25195000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46002000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.55
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46002000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.55
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45800000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 17:16:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.55
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,188398000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,188398000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,26482000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,26482000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,161916000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,39520000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,35142000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,23758000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,157000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,257317000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,24100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,379994000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-218078000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4881000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,33000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-85000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4933000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-223011000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-51947000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-171064000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-171064000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-171064000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45999000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.72
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45999000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.72
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.72
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,106165000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,106165000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20634000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20634000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,85531000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,47601000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30560000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,716000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,6200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,85077000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,454000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5497000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,326000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5176000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4722000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3477000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8199000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8199000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8199000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46529000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46529000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:09:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,303714000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,303714000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,30378000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,30378000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,273336000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,44263000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25910000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,716000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,150412000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-7000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,214301000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,59035000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5414000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,910000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,22000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4482000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,54553000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8400000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,46153000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,46197000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,46197000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46799000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.99
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47201000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.98
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46700000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 07:27:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.99
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,282787000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,282787000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,25152000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,25152000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,257635000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,43571000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22855000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,239000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,139973000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,22700000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,229338000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,28297000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5415000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1176000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4240000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,24057000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,37968000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13911000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13911000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13911000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47184000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47184000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48000000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 17:11:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-221233000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-221233000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,21476000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,21476000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-242709000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,36819000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27058000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,-1000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-290385000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,33100000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-193409000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-49300000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5271000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1106000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4165000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-53465000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-63104000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9639000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9595000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9595000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47010000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.2
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47341000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.2
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46800000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.2
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,44137000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,44137000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8799000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8799000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,35338000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,52725000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16028000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2564000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,7400000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,78717000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-43379000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6424000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1496000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-13000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4941000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-48320000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-715000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-47605000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-47605000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-47605000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47472000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47472000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47600000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 17:17:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,97244000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,97244000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9397000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9397000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,87847000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,50195000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18959000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,7691000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,47191000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-12800000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,111236000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23389000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5378000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1498000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3883000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27272000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,200000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27472000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27486000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27486000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47486000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.58
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47486000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.58
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47400000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 07:27:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.58
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,92522000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,92522000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7986000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7986000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,84536000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48702000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16073000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,7692000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,44800000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,277561000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-50942000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,343886000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-259350000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4500000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,333000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4168000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-263518000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,17000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-263535000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-263535000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-263535000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47511000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-5.55
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47511000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-5.55
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47500000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 17:11:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-5.55
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-41495000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-41495000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8667000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8667000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-50162000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,41224000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9023000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,7689000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-91991000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-30593000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-64648000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,14486000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-49503000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,843000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,30000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,50376000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,64862000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-784000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,65646000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,65660000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,65660000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47512000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.38
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47512000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.38
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47500000.0
Acorda Therapeutics Inc,ACOR,5493007NPB5YRM8QGL53,0001008848,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.38
